Technology Use and Glycemic Outcomes during Pregnancy with Type 1 Diabetes

This editorial discusses advancements in managing type 1 diabetes during pregnancy, emphasizing the role of closed-loop insulin delivery systems and continuous glucose monitoring (CGM). The authors highlight the AiDAPT trial, which demonstrated that closed-loop systems significantly improved time-in-range (TIR) for pregnant women compared to standard insulin therapy, without increasing hypoglycemia. Despite these benefits, unanswered questions remain, such as the optimal timing for initiating closed loop therapy and its impact on neonatal outcomes. The editorial calls for further research, regulatory approvals, and equitable access to these technologies to improve maternal and fetal health outcomes globally.

This editorial discusses advancements in managing type 1 diabetes during pregnancy, emphasizing the role of closed-loop insulin delivery systems and continuous glucose monitoring (CGM). The authors highlight the AiDAPT trial, which demonstrated that closed-loop systems significantly improved time-in-range (TIR) for pregnant women compared to standard insulin therapy, without increasing hypoglycemia. Despite these benefits, unanswered questions remain, such as the optimal timing for initiating closed loop therapy and its impact on neonatal outcomes. The editorial calls for further research, regulatory approvals, and equitable access to these technologies to improve maternal and fetal health outcomes globally.